Yaralar için Polivinil Alkol (PVA) (Tıbbi Filmler)

Managing exudate in partial-thickness burns demands a dressing that can absorb up to 5–7 g/g of wound fluid while maintaining a moist interface without maceration of the peri-wound skin. Polyvinyl alcohol (PVA) films, cast from aqueous solutions, provide a transparent, conformable barrier that meets these requirements through a combination of high water uptake and controlled moisture vapor transmission rate (MVTR). Unlike solvent-based coatings, the water-based casting process eliminates cytotoxic residual solvents, aligning with ISO 10993-5:2009 cytotoxicity criteria (elution test, L929 cells, viability > 70%). The oxygen permeability of an unplasticised PVA film at 23°C and 50% RH is approximately 0.5–1.5 cm³·mm/(m²·day·atm) per ASTM D3985, sufficiently low to prevent desiccation yet not so low as to promote anaerobiosis. PVA achieves these properties without requiring plasticisers that could leach and irritate wound tissue, because partial hydrolysis introduces molecular irregularities that reduce crystallinity and confer intrinsic flexibility.

What Degree of Hydrolysis Is Required for High-Integrity Medical Films?

PVA grades suitable for solvent-cast medical films typically exhibit a degree of hydrolysis between 98.0 and 99.8 mol% (fully hydrolysed) for maximum crystallinity and mechanical integrity, while partially hydrolysed grades (87–89 mol%) offer faster dissolution and reduced stiffness. The 4% aqueous solution viscosity at 20°C ranges from 4.5 to 6.5 mPa·s for low‑molecular‑weight types (e.g., PVA‑105, approximate M_w 22,000–31,000 g/mol) and 25–30 mPa·s for medium‑viscosity grades (PVA‑117, M_w 75,000–95,000 g/mol by SEC‑MALS). Residual acetyl content below 2.0 mol% limits water sensitivity while preserving sufficient interfacial interaction for secondary dressing adhesion. These specifications correspond with the Ph. Eur. monograph 01/2023:1163 for poly(vinyl alcohol) as a pharmaceutical excipient. In practice, fully hydrolysed grades are preferred for films requiring high wet strength; however, their tendency to form crystalline domains during drying can lead to brittle failure if the film thickness exceeds 100 μm. For transparent, flexible films under 75 μm, formulators often blend a high‑hydrolysis grade with a small fraction of partially hydrolysed PVA to disrupt crystallinity without sacrificing water resistance.

Casting PVA Solutions into Medical Films Using Slot‑Die Technology

The conversion of PVA solution to a uniform medical film relies on slot‑die coating onto a siliconised polyester release liner. A dope of 10–15 wt% PVA in deionised water is prepared at 85–95°C under low‑shear mechanical agitation for 30–60 minutes. The solution is passed through a 5 μm absolute‑rated filter capsule and degassed under −0.8 bar vacuum. A slot‑die coater equipped with a 150 mm-wide die and a high‑precision syringe pump (e.g., TSE Troller or equivalent closed‑loop system) delivers a wet film at a gap of 200–400 μm and a coating speed of 1–3 m/min, yielding a wet thickness of 250–500 μm. Drying in a multi‑zone forced‑air oven with temperature ramping from 60°C to 110°C over 15–20 minutes reduces residual moisture to ≤5 wt%, monitored by Karl Fischer titration (ASTM D6869). Films produced in this manner exhibit thickness uniformity within ±5% as measured by a non‑contact laser gauge, critical for consistent MVTR and fluid handling. Any deviation from the drying profile that leaves moisture above 8 wt% leads to blocking on the roll and necessitates re‑drying; conversely, overdrying above 130°C can induce thermally activated crosslinking between hydroxyls, altering solubility and potentially affecting subsequent crosslinking steps.

When Crosslinking Agents Affect Biocompatibility and Mechanical Resilience

Uncrosslinked PVA films remain water‑soluble and lose integrity within minutes of wound exudate contact, so chemical or physical crosslinking is mandatory. Glutaraldehyde at 0.5% v/v in 0.1 M HCl/ethanol provides rapid acetal crosslinks, but residual aldehyde must be reduced below 50 ppm (HPLC with UV detection at 365 nm after DNPH derivatisation) to satisfy ISO 10993‑5 cytotoxicity limits; extended washing in glycine‑buffered water for 48 h is typical. An alternative, citric acid combined with sodium hypophosphite catalyst (0.5 wt% on PVA) and heat curing at 140°C for 5 minutes produces ester crosslinks with no leachable toxic residuals, achieving gel fractions above 85% (gravimetric after 24 h water extraction). Physical crosslinking via repeated freeze‑thaw cycles in a programmable chamber (−20°C for 8 h, +25°C for 4 h) forms crystallite‑based junction zones, yielding cryogel films with an exceptional fluid absorption capacity of 12–15 g/g (EN 13726‑1, free swell). The mechanical properties after crosslinking are assessed by ASTM D882 (tensile, 500 mm/min): glutaraldehyde‑crosslinked films typically show ultimate tensile strength of 25–35 MPa at 200–300% elongation, while freeze‑thaw cryogels exhibit lower strength (15–22 MPa) but higher elongation (350–500%). Selection must balance mechanical robustness against the risk of chemical sensitisation; for paediatric or chronic wounds, physical crosslinking is favoured despite longer processing time.

PVA Outperforms Polyurethane in Fluid Handling But Not in Conformability

Comparative evaluation of transparent wound dressing films according to EN 13726‑1 free swell absorptive capacity and ASTM D882 tensile properties reveals distinct performance clusters that guide product selection for wound types. PVA films occupy a unique space: they absorb several times their weight in fluid while remaining transparent and non‑adherent to the wound bed, unlike hydrocolloids that become opaque and leave residue. The oxygen and water vapour transmission rates of PVA can be engineered by adjusting crystallinity and thickness; polyurethane films, by contrast, provide higher MVTR (> 2000 g/m²/24h per ASTM E96, upright cup) but negligible fluid absorption, making them less suitable for moderate to heavy exudate unless combined with an absorbent pad. Alginate dressings offer high absorbency but are opaque, forming a gel that can obscure wound visualisation and require a secondary dressing. Chitosan films possess intrinsic haemostatic and antimicrobial activity but exhibit low wet‑state tensile strength (5–12 MPa) that limits their use on mobile anatomical sites. The matrix below summarises key metrics for common dressing film materials, with all values obtained under controlled laboratory conditions at 23 ± 2°C and 50 ± 5% RH.

The functional response of PVA wound films is inseparably linked to the resin’s degree of polymerisation and hydrolysis. Producers targeting rapid dissolution for in‑situ gelling applications select low‑viscosity, partially hydrolysed grades, while those requiring durable, free‑standing films choose fully hydrolysed, medium‑viscosity types. The table below lists commercial PVA grades commonly evaluated in medical film development, with typical specifications derived from manufacturer certificates of analysis and compendial monographs. All viscosity data correspond to 4% aqueous solutions at 20°C (Brookfield LV, spindle 1, 60 rpm).

In donor site wounds, where fluid loss is high and bacterial barrier essential, a PVA film of thickness 80–120 μm crosslinked by two freeze‑thaw cycles (−20°C for 8 h, +25°C for 4 h) delivers an absorptive capacity of 12–15 g/g (EN 13726‑1, free swell) and a tensile strength exceeding 18 MPa (ASTM D882). The film’s MVTR, measured by upright cup method (ASTM E96, 23°C, 50% RH), averages 900–1100 g/m²/24h, maintaining a moist wound environment while preventing fluid pooling. The dressing remains transparent throughout the wear time of up to 72 hours, allowing clinicians to monitor healing without disruption. A limitation of physically crosslinked PVA cryogels is their susceptibility to drying‑out if left uncovered; hence they are typically overlaid with a polyurethane film that provides a moisture vapour‑permeable, waterproof top layer. Published data for this specific donor site configuration remains limited, but bench‑top fluid handling models (EN 13726‑3) suggest that the composite dressing maintains an interface humidity of 85–95% RH, conducive to epithelialisation. In contrast, calcium alginate dressings would gel and require a secondary securement, obscuring the wound bed and increasing the risk of periwound maceration from lateral wicking.